Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India

Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.

India Regulation

Sanofi's €10bn Dupixent Plan: "We're Going To Put The JAKs Properly In Their Place"

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Inflammation Immune Disorders

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

BioPharmaceutical Financing

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

China Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register